Objective To investigate the clinical efficacy of paclitaxel combined with three-dimensional conformal ra-diotherapy(3DCRT) for advanced non-small cell lung cancer(NSCLC) in the elderly. Methods From June 2011 to June 2013, 51 elderly patients with NSCLC were randomly divided into chemoradiotherapy group (n=26) and chemotherapy group(n=25). All patients were treated with weekly 60 mg/m2 of paclitaxel intravenously for 3 weeks, and patients in the chemoradiotherapy group were also treated with three-dimensional conformal radiation (1.8~2.0 Gy per fraction, 5 times per week, total dose of 60~66 Gy). The clinical efficacy and adverse reactions were compared between two groups. Re-sults In chemoradiotherapy group, the response rate was 84.6% and the overall efficiency rate was 96.2%, which were higher than 60.0% and 84.0% in chemotherapy group (P<0.05). In chemoradiotherapy group, the one year survival rate was 79.2%, which was higher than 61.5% in chemotherapy group (P<0.05), so did one year progression free survival rates (67.4% vs 40.0%)(P<0.05). The main side effects were gastrointestinal toxicity, radiation esophagitis and bone-marrow suppression. Conclusion Paclitaxel combined with three-dimensional conformal radiotherapy for advanced NSCLC in the elderly are safe and effective, the toxicity is tolerable.%目的：观察泰素(紫杉醇)单药联合三维适形放疗同步治疗老年晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法选择2011年6月~2013年6月我院收治的51例70~82岁的老年晚期NSCLC患者，随机分为同步放化疗组(同步组，26例)和单纯化疗组(单化组，25例)。单化组采用单药泰素化疗，应用周剂量泰素60 mg/m2，1次/周，连用3周，休息1周后继续下1个疗程，同步组在此基础上接受三维适形放疗(1.8~2.0)Gy/次/d，5次/周，总照射剂量60~66 Gy。评价和分析治疗结束后两周两组的临床疗效和不良反应。结果同步组治疗总有效率和临床获益率分别为84.6%和96.2%，均明显高于单化组的60.0%、84.0%(P<0.05)。两组的1年总生存率分别为79.2%、61.5%(P<0.05)，两组的1年无进展生存率分别为67.4%、40.0%(P<0.05)。主要的不良反应为轻度胃肠道反应、放射性食管炎和Ⅰ~Ⅲ度骨髓抑制。结论泰素单药联合同步三维适形放疗治疗老年晚期NSCLC疗效较好，不良反应轻，毒副反应能耐受。
展开▼
